Stoke Therapeutics, Inc. Logo

Stoke Therapeutics, Inc.

Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.

STOK | US

Overview

Corporate Details

ISIN(s):
US86150R1077
LEI:
Country:
United States of America
Address:
45 WIGGINS AVENUE, 1730 BEDFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines to treat severe genetic diseases. The company's proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), aims to restore normal protein levels by increasing—or "stoking"—protein expression from the healthy copy of a mutated gene. This approach is primarily designed to address haploinsufficiencies, where a single functional gene is insufficient to prevent disease. Stoke's lead candidate, zorevunersen (STK-001), is in clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company's pipeline also includes programs for other genetic disorders, such as autosomal dominant optic atrophy (ADOA).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Stoke Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Stoke Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Stoke Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.